1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
2.3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Drug, 2025 (US$ Million)
2.4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025

3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Amyotrophic Lateral Sclerosis (ALS) Treatment Market Vendors
3.2. Strategies Adopted by Amyotrophic Lateral Sclerosis (ALS) Treatment Market Vendors

4. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Riluzole
5.3.2. Edaravone
5.3.3. Other

6. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
6.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)

7. UK and European Union Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)

8. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)

9. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
9.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)

10. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
10.3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Amyotrophic Lateral Sclerosis (ALS) Treatment Market: By Drug, 2024-2034, USD (Million)

11. Company Profile
11.1. AB Science (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Avicena Group
11.3. Biogen
11.4. BrainStorm Therapeutics
11.5. Covis Pharmaceutical Inc.
11.6. Cytokinetics Inc.
11.7. Eisai Co. Ltd.
11.8. GlaxoSmithKline plc.
11.9. Ionis Pharmaceuticals, Inc.
11.10. Mitsubishi Tanabe Pharma Corp.
11.11. Neuralstem Inc.
11.12. Neuraltus Pharmaceuticals Inc.
11.13. Newron Pharmaceuticals S.p.A.
11.14. Pharnext SAS
11.15. Q-Therapeutics Inc.